COLLEGIUM PHARMACEUTICAL, INC Quarterly Deferred Income Tax Expense (Benefit) in USD from Q3 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Collegium Pharmaceutical, Inc quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q3 2019 to Q1 2024.
  • Collegium Pharmaceutical, Inc Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$4.41M, a 9491% decline year-over-year.
  • Collegium Pharmaceutical, Inc annual Deferred Income Tax Expense (Benefit) for 2023 was -$2.15M, a 74.3% increase from 2022.
  • Collegium Pharmaceutical, Inc annual Deferred Income Tax Expense (Benefit) for 2022 was -$8.39M, a 89.2% increase from 2021.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$4.41M -$4.37M -9491% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q1 2023 -$46K +$5.99M +99.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q1 2022 -$6.04M -$6.04M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q2 2021 -$62.6M Apr 1, 2021 Jun 30, 2021 10-Q 2021-08-05
Q1 2021 $0 $0 Jan 1, 2021 Mar 31, 2021 10-Q 2021-05-06
Q3 2020 $0 $0 Jul 1, 2020 Sep 30, 2020 10-Q 2020-11-05
Q1 2020 $0 Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q3 2019 $0 Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.